2017 Cannabis Clinical Trials Safety 
NORML
MAY 26, 2020
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo. .”
Cannabis Law Report
JUNE 10, 2021
In short the study learns that legalized states tend not to have their roads overcrowded with stoned drivers and cannabis users like alcohol users self police their behaviour. The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Materials and methods.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 7, 2021
Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Eight studies were included, all of which are randomized controlled trials. 1.69, 95% CI [1.20–2.36])
The Cannigma
FEBRUARY 2, 2021
This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.
The Cannigma
AUGUST 31, 2021
Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. People want to trust their doctors, but doctors need knowledge. We have a ways to go,” Tan said.
Cannabis Law Report
MAY 29, 2022
To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. In 2017, FDA granted a request for Breakthrough Therapy designation for MDMA to treat PTSD.
Cannabis Law Report
JULY 1, 2021
Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression. The Project.
Expert insights. Personalized for you.
239 
Let's personalize your content